Author:
Han Xu,Li Hui,Dong Sha-Sha,Zhou Shui-Ying,Wang Cai-Hong,Guo Lin,Yang Jie,Zhang Gang-Ling
Abstract
Abstract
Objective
To analyze the factors related to the efficacy of neoadjuvant therapy for breast cancer and find appropriate evaluation methods for evaluating the efficacy of neoadjuvant therapy
Methods
A total of 143 patients with breast cancer treated by neoadjuvant chemotherapy at Baotou Cancer Hospital were retrospectively analyzed. The chemotherapy regimen was mainly paclitaxel combined with carboplatin for 1 week, docetaxel combined with carboplatin for 3 weeks, and was replaced with epirubicin combined with cyclophosphamide after evaluation of disease progression. All HER2-positive patients were treated with simultaneous targeted therapy, including trastuzumab single-target therapy and trastuzumab combined with pertuzumab double-target therapy. Combined with physical examination, color Doppler ultrasound, and magnetic resonance imaging (MRI), a systematic evaluation system was initially established—the “triple evaluation method.” A baseline evaluation was conducted before treatment. The efficacy was evaluated by physical examination and color Doppler every cycle, and the efficacy was evaluated by physical examination, color Doppler, and MRI every two cycles.
Results
The increase in ultrasonic blood flow after treatment could affect the efficacy of monitoring. The presence of two preoperative time–signal intensity curves is a therapeutically effective protective factor for inflow. The triple evaluation determined by physical examination, color Doppler ultrasound, and MRI in determining clinical efficacy is consistent with the effectiveness of the pathological gold standard.
Conclusion
The therapeutic effect of neoadjuvant therapy can be better evaluated by combining clinical physical examination, color ultrasound, and nuclear magnetic resonance evaluation. The three methods complement each other to avoid the insufficient evaluation of a single method, which is convenient for most prefecty-level hospitals. Additionally, this method is simple, feasible, and suitable for promotion.
Publisher
Springer Science and Business Media LLC
Reference32 articles.
1. Cortazar P, Zhang L, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. [J]. Lancet. 2014;384:164–72.
2. China Breast Cancer neoadjuvant Therapy Expert Group. Expert consensus on neoadjuvant treatment of breast cancer in China (2021 edition). China Oncol. 2022;32(1):80–89. https://doi.org/10.19401/j.cnki.1007-3639.2022.01.011.
3. Chen M, Zhan WW, Han BS, Fei XC, Jin XL, Chai WM, et al. Accuracy of physical examination, ultrasonography, and magnetic resonance imaging in predicting response to neo-adjuvant chemotherapy for breast cancer. Chin Med J. 2012;125(11):1862–6. PMID: 22884043
4. Kato E, Mori N, Mugikura S, Sato S, Ishida T, Takase K. Value of ultrafast and standard dynamic contrast-enhanced magnetic resonance imaging in the evaluation of the presence and extension of residual disease after neoadjuvant chemotherapy in breast cancer. Jpn J Radiol. 2021;39(8):791–801. https://doi.org/10.1007/s11604-021-01110-y. Epub 2021 Mar 20. PMID: 33743147
5. Matsuda N, Kida K, Ohde S, Suzuki K, Yamauchi H, Nakamura S, et al. Change in sonographic brightness can predict pathological response of triple-negative breast cancer to neoadjuvant chemotherapy. Breast Cancer. 2018;25(1):43–9. https://doi.org/10.1007/s12282-017-0782-z. Epub 2017 May 23. PMID: 28536943